• info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) | +1-214-736-7666 (US) | +1-740-994-0111 (US)
  • Sign In
  • Register

Pharmaceuticals & HealthcareNarcolepsy - Pipeline Review, H2 2018

  • RnM2474168
  • |
  • 9 October, 2018
  • |
  • Global
  • |
  • 88 pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Narcolepsy - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2018, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 4, 4, 5, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Narcolepsy - Overview
Narcolepsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Narcolepsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Narcolepsy - Companies Involved in Therapeutics Development
Avadel Pharmaceuticals Plc
Bioprojet SCR
Evotec AG
F. Hoffmann-La Roche Ltd
H.A.C. Pharma
Heptares Therapeutics Ltd
Jazz Pharmaceuticals Plc
Ono Pharmaceutical Co Ltd
OptiNose US Inc
SK Biopharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Theranexus SAS
Narcolepsy - Drug Profiles
(flecainide acetate + modafinil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-386 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentylenetetrazol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pitolisant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solriamfetol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVNG-3031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XW-10172 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XW-10282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Narcolepsy - Dormant Projects
Narcolepsy - Discontinued Products
Narcolepsy - Product Development Milestones
Featured News & Press Releases
Sep 10, 2018: XW Labs appoints clinical development veteran Dr. Daniel Canafax as Chief Medical Officer
Sep 05, 2018: Harmony Biosciences to present data on its investigational product, Pitolisant, at upcoming International Narcolepsy Symposium
Jun 27, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy
Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea
Jun 01, 2018: Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA
May 31, 2018: Harmony Biosciences to Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting
May 22, 2018: Bioprojet: Pitolisant Progresses Towards the U.S. Market
May 21, 2018: Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant
May 10, 2018: Jazz Pharmaceuticals to Present Data on Sodium Oxybate at SLEEP 2018 Annual Meeting
May 10, 2018: Jazz Pharmaceuticals to Present Data on Solriamfetol at SLEEP 2018 Annual Meeting
May 01, 2018: Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Mar 22, 2018: AOP Orphan will distribute Wakix (pitolisant) from Bioprojet Pharma in Austria, Nordic countries and Central Eastern Europe
Mar 12, 2018: XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment
Mar 02, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


captcha
Enter the code in the box:


captcha
Enter the code in the box:

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.


captcha
Enter the code in the box:



Summary:
Get latest Market Research Reports on Narcolepsy. Industry analysis & Market Report on Narcolepsy is a syndicated market report, published as Narcolepsy - Pipeline Review, H2 2018. It is complete Research Study and Industry Analysis of Narcolepsy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$2,000.00
$4,000.00
$6,000.00
1,343.00
2,686.00
4,029.00
1,840.40
3,680.80
5,521.20
242,280.00
484,560.00
726,840.00
132,626.80
265,253.60
397,880.40
Add To Cart Credit card Logo

Related Reports


Reason to Buy